Ichiba S, Bartlett R H
University of Michigan Medical Center, Ann Arbor 48109, USA.
Artif Organs. 1996 Feb;20(2):120-3. doi: 10.1111/j.1525-1594.1996.tb00712.x.
Extracorporeal membrane oxygenation (ECMO) for respiratory failure was reviewed. ECMO progressed from laboratory research to initial clinical trials in 1972. Following a decade of clinical research, ECMO is now standard treatment for neonatal respiratory failure refractory to conventional pulmonary support techniques worldwide. The application of neonatal ECMO has been extended with improved outcome to premature and low birth weight infants as well as older children and adults. As of July 1994, 9,258 neonates, 754 pediatric, and 130 adult patients with respiratory failure treated with ECMO were entered in the registry of the Extracorporeal Life Support Organization (ELSO). Overall survival rates were 81% in neonates, 49% in pediatric, and 38% in adult patients. Recently the adult and pediatric populations treated with ECMO have increased rapidly, and the outcome has improved significantly.
对用于呼吸衰竭的体外膜肺氧合（ECMO）进行了综述。ECMO从实验室研究发展到1972年的初步临床试验。经过十年的临床研究，ECMO现在是全球范围内对传统肺部支持技术无效的新生儿呼吸衰竭的标准治疗方法。随着治疗效果的改善，新生儿ECMO的应用范围已扩大到早产儿、低体重儿以及大龄儿童和成人。截至1994年7月，接受ECMO治疗的9258例新生儿、754例儿科患者和130例呼吸衰竭成人患者被纳入体外生命支持组织（ELSO）的登记系统。新生儿的总体生存率为81%，儿科患者为49%，成人患者为38%。最近，接受ECMO治疗的成人和儿科患者数量迅速增加，治疗效果也有显著改善。
